Loading ...
Sorry, an error occurred while loading the content.

FW: NATAP: New HCV Drug enters pre-clinical

Expand Messages
  • alleypat
    Arrow Therapeutics selects Hepatitis C clinical candidate London, 6th February 06, Arrow Therapeutics, the London based antiviral drug discovery and
    Message 1 of 1 , Feb 7, 2006
    • 0 Attachment
      Arrow Therapeutics selects
      Hepatitis C clinical candidate

      London, 6th February 06, Arrow Therapeutics, the London based antiviral drug
      discovery and development company, has announced that its lead Hepatitis C
      compound has entered full preclinical development.

      Originating from Arrow's focused chemical library and optimised in-house,
      the compound (A-831) has shown potent activity in the replicon assay and has
      an excellent therapeutic index and good pharmacokinetic properties, as well
      as displaying a novel mechanism of action targeting the NS5a protein. Phase
      I trials on the compound are planned for the second half of 2006, by which
      time a further compound from Arrow's second Hepatitis C programme (also
      targeting the NS5a protein) is expected to enter preclinical development.

      The urgent need for novel Hepatitis C inhibitors has been well documented,
      with an estimated 170 million sufferers worldwide. The current treatment
      (Pegylated Interferon + ribavirin) has a poor side effect profile, is very
      expensive and is only effective in around 50% of patients. As with HIV/AIDS,
      multiple drugs in combination therapy are likely to be needed to overcome
      drug resistance. The value of the Hepatitis C market was approximately $3
      billion in 2004 and is forecast to grow substantially, to greater than $6
      billion in the next 5-7 years.

      Arrow's CEO, Ken Powell, speaks of his delight at the advancements made
      within the programme, bWe have been working hard on our Hepatitis C
      programmes since the foundation of the company. Arrow's compounds have a
      novel mechanism and show potent activity in the replicon assay - now well
      validated as a predictor of clinical activity through the work of Vertex and
      others. We regard NS5a as an excellent target, and these inhibitors should
      find an important place as constituents of combination regimens. The entry
      of the first programme into full preclinical development is an exciting step
      in the development of a novel therapyb.




      ----------

      _______________________________________________
      NATAP nataphcv mailing list -- nataphcv@...

      This is an annoucement-only mailing list. Do not reply.

      To unsubscribe: send a blank email to nataphcv-request@... with a subject of unsubscribe.


      For more information, see http://seven.pairlist.net/mailman/listinfo/nataphcv

      _______________________________________________


      [Non-text portions of this message have been removed]
    Your message has been successfully submitted and would be delivered to recipients shortly.